Speaking To AstraZeneca And Huma About Digital’s Value For Pharma
AstraZeneca has been working with Huma to develop a series of software-based tools for monitoring patients. Medtech Insight spoke to both companies about the value of these partnerships and the potential challenges.
You may also be interested in...
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb discusses conference highlights from SXSW and LSI while Barnaby Pickering talks about his coverage on voice biomarkers. Hannah Daniel discusses BetterHelp’s return of $7.8m to customers to settle with FTC for sharing health data.
Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.
The companies will continue to collaborate to expand the reach of AstraZeneca's Amaze platform for chronic disease while launching companion applications.